Table 4.

Unadjusted and multivariable analyses of predictors of downstaging in the all-comers cohort (n = 82).

Predictor	Hazard ratio (95% CI)	P-value
Unadjusted analysis
Age (per y)	1.00 (0.97–1.04)	.84
Female (vs male)	0.88 (0.37–2.08)	.78
Etiology of liver disease
NAFLD (vs hepatitis C)	0.92 (0.44–1.90)	.82
Alcohol (vs hepatitis C)	0.46 (0.18–1.19)	.11
Other including hepatitis B or > 1 diagnosis (vs hepatitis C)	0.73 (0.35–1.51)	.39
MELD score (per point)	1.02 (0.95–1.10)	.54
Child’s B/C cirrhosis (vs A)	1.03 (0.52–2.04)	.92
AFP before LRT (ng/mL)
≥ 20 (vs < 20)	0.60 (0.34–1.03)	.07
≥ 100 (vs < 100)	0.70 (0.37–1.30)	.25
≥ 500 (vs < 500)	0.32 (0.1–1.03)	.06
≥ 1000 (vs < 1000)	0.19 (0.03–1.40)	.10
Total tumor burden (per cm)	0.95 (0.88–1.04)	.27
Number of lesions + largest lesion diameter (per unit)	0.88 (0.77–1.01)	.06
Number of HCC lesions	1.04 (0.89–1.22)	.59
Systemic therapy (vs none)	0.35 (0.11–1.1)	.07
Multivariable analysis
Number of lesions + largest lesion diameter (per unit)	0.86 (0.75–0.99)	.04

Abbreviations: AFP, alpha-fetoprotein; CI, confidence interval; HCC, hepatocellular carcinoma; MELD, Model for End-Stage Liver Disease; NAFLD, nonalcoholic fatty liver disease; LRT, local regional therapy.Abbreviations: AC, all-comers; CTP, Child-Turcotte-Pugh; HCC, hepatocellular carcinoma; IQR, interquartile range; LRT, local regional therapy; LT, liver transplantation; MELD, Model for End-Stage Liver Disease; NAFLD, nonalcoholic fatty liver disease; TACE, transarterial chemoembolization; UNOS-DS, United Network for Organ Sharing-downstaging; Y-90, Yttrium-90.